TGA has invited submissions on its consultation paper released last Thursday designed to facilitate indication...
TGA seeks consultation on issues relating to the registration of off-label use of medicines: Part 1
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
Naomi is listed in IAM Patent 1000 as one of Australia's leading patent litigators. Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries, resulting from first hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.
See Naomi's full profile
Pearce IP BioBlast®: w/e 05 February 2021
29 Jan 21 | EU | The CHMP recommended 13 medicines for approval. Among the recommendations were two bevacizumab...
Pearce IP BioBlast®: w/e 29 January 2021
25 Jan 21 | Samsung Bioepis announced the opening of its new headquarters in Incheon. The building was complete in...
Pearce IP BioBlast®: w/e 22 January 2021
18 Jan 21 | Prestige Biopharma announced it is set for an IPO in early February 2021. The IPO is expected to be worth...
Pearce IP BioBlast™: w/e 15 January 2021
07 Jan 21 | ADQ announced it will acquire Pharmax Pharmaceuticals, as well as investing in a minority stake in Biocon...
Pearce IP BioBlast™: w/e 08 January 2021
05 Jan 21 | EU | The Centre for Biosimilars reported a study presented at the 2020 San Antonio Breast Cancer Symposium...
Pearce IP BioBlast™: w/e 01 January 2021
27 Dec 20 | CN | Innovent announced China's NMPA has approved Byvasda® (biosimilar bevacizumab) for the additional...
Pearce IP BioBlast™: w/e 25 December 2020
21 Dec 20 | Celltrion announced Ph III trials of its proposed ustekinumab biosimilar CT-P43 will be completed by the...
Supply of essential oil for topical use infringes method of treatment patent claims
Supply of essential oil for topical use infringes method of treatment patent claims Justice Nicholas’ 96-page judgment...
Pearce IP BioBlast™: w/e 18 December 2020
12 Dec 20 | Biopharma supplier Alexion announced it will be acquired by AstraZeneca. The acquisition is expected to...
Pearce IP BioBlast™: w/e 11 December 2020
24 Nov 20 | Novartis released its annual report 'Meet Novartis Management 2020'. In the report, Novartis announced...
Biologics dominate list of costliest drugs
On 01 December NPS Medicine Wise published its annual list of the top 10 PBS drugs by cost to the Australian...
Jane Halton appointed as GBMA Chair
The Generic and Biosimilar Medicines Association announced it has appointed Ms Jane Halton AO PSM as its inaugural...
Pearce IP BioBlast™: w/e 04 December 2020
24 Nov 20 | Novartis released its annual report 'Meet Novartis Management 2020'. In the report, Novartis announced...
Pearce IP BioBlast™: w/e 27 November 2020
22 Nov 20 | Innovent released results of Ph III trials of Tyvyt® (sintilimab) with Byvasda® (biosimilar bevacizumab)...
Preliminary discovery not justified by fear of a future product launch
In Pfizer Ireland Pharmaceuticals v Sandoz Pty Ltd [2020] FCA 1648, the Federal Court of Australia declined to order...